PL402948A1 - Kwasy tluszczowe o sredniej dlugosci lancucha, glicerydy i analogi jako czynniki zwiekszajace przezycie i aktywacje neutrofili - Google Patents

Kwasy tluszczowe o sredniej dlugosci lancucha, glicerydy i analogi jako czynniki zwiekszajace przezycie i aktywacje neutrofili

Info

Publication number
PL402948A1
PL402948A1 PL402948A PL40294802A PL402948A1 PL 402948 A1 PL402948 A1 PL 402948A1 PL 402948 A PL402948 A PL 402948A PL 40294802 A PL40294802 A PL 40294802A PL 402948 A1 PL402948 A1 PL 402948A1
Authority
PL
Poland
Prior art keywords
medium chain
neutrophils
survival
activation
fatty acids
Prior art date
Application number
PL402948A
Other languages
English (en)
Other versions
PL222876B1 (pl
Inventor
Lyne Gagnon
Jean Barabe
Pierre Laurin
Christopher Penney
Boulos Zacharie
Original Assignee
Prometic Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc. filed Critical Prometic Biosciences Inc.
Publication of PL402948A1 publication Critical patent/PL402948A1/pl
Publication of PL222876B1 publication Critical patent/PL222876B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/003—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with alcohols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Wynalazek dotyczy kompozycji i sposobu zwiekszania przezycia i aktywacji neutrofili, np. w przypadku leczenia neutropenii bedacej niepozadanym skutkiem ubocznym chemioterapii i radioterapii. Kompozycje zawierajaca kwasy tluszczowe o sredniej dlugosci lancucha, takie jak kwas kaprynowy lub kwas kaprylowy, lub ich sole albo triglicerydy, albo ich mono- lub diglicerydy lub inne analogi, albo triglicerydy o sredniej dlugosci lancucha (MCT), podaje sie czlowiekowi lub zwierzeciu potrzebujacemu leczenia w ilosci wystarczajacej do zmniejszenia lub wyleczenia neutropenii. Kompozycje podaje sie w ilosci skutecznej do leczenia tego zaburzenia. Ujawnione sposoby sa takze uzyteczne w przeszczepianiu szpiku kostnego i w leczeniu róznych chorób zwiazanych z neutropenia.
PL402948A 2001-04-18 2002-04-18 Zastosowanie pochodnych glicerolu PL222876B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28445801P 2001-04-18 2001-04-18

Publications (2)

Publication Number Publication Date
PL402948A1 true PL402948A1 (pl) 2013-05-13
PL222876B1 PL222876B1 (pl) 2016-09-30

Family

ID=23090294

Family Applications (2)

Application Number Title Priority Date Filing Date
PL366435A PL223348B1 (pl) 2001-04-18 2002-04-18 Zastosowanie karboksylanu
PL402948A PL222876B1 (pl) 2001-04-18 2002-04-18 Zastosowanie pochodnych glicerolu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL366435A PL223348B1 (pl) 2001-04-18 2002-04-18 Zastosowanie karboksylanu

Country Status (30)

Country Link
US (2) US7745488B2 (pl)
EP (2) EP1385498B1 (pl)
JP (3) JP5026655B2 (pl)
KR (1) KR20030096323A (pl)
CN (1) CN1633286A (pl)
AP (1) AP1740A (pl)
AU (2) AU2002308456B2 (pl)
BG (1) BG66418B1 (pl)
BR (1) BR0208984A (pl)
CA (2) CA2444463C (pl)
CY (1) CY1107081T1 (pl)
CZ (1) CZ305273B6 (pl)
DE (1) DE60223670T2 (pl)
DK (2) DK1900364T3 (pl)
EA (1) EA007322B1 (pl)
EE (1) EE200300510A (pl)
ES (2) ES2295397T3 (pl)
HU (1) HUP0303817A3 (pl)
IL (3) IL158322A0 (pl)
MX (1) MXPA03009436A (pl)
NO (1) NO335105B1 (pl)
NZ (2) NZ541140A (pl)
OA (1) OA12506A (pl)
PL (2) PL223348B1 (pl)
PT (2) PT1900364E (pl)
SI (1) SI1385498T1 (pl)
SK (1) SK12772003A3 (pl)
TN (1) TNSN03089A1 (pl)
WO (1) WO2002083120A2 (pl)
ZA (1) ZA200307778B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1900364T3 (da) 2001-04-18 2014-01-13 Prometic Biosciences Inc Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer
BRPI0407276A (pt) * 2003-02-07 2006-01-31 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese
PL1648851T3 (pl) 2003-07-25 2007-09-28 Prometic Biosciences Inc Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
AP2007003939A0 (en) * 2004-09-03 2007-04-30 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
EA200700741A1 (ru) 2004-10-01 2007-08-31 Прометик Байосайенсиз Инк. Жирные спирты со средней длиной цепи как стимуляторы гематопоэза
JP5179198B2 (ja) * 2005-02-28 2013-04-10 アルファベータ エイビー アミロイドベータ−ペプチドの凝集を低減する化合物
CA2687446A1 (en) 2006-05-17 2007-11-29 Cognate Therapeutics, Inc. Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
US9532962B2 (en) * 2007-11-02 2017-01-03 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
JP5473937B2 (ja) * 2007-12-19 2014-04-16 プロメティック・バイオサイエンシーズ・インコーポレイテッド 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CN102099024B (zh) 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
RU2678833C2 (ru) * 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
EP2165713B1 (en) * 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
BR112014028094B1 (pt) * 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
CA2921845C (en) 2013-08-19 2018-07-10 Korea Research Institute Of Bioscience And Biotechnology Compositions containing monoacetyldiacylglycerol compound as an active indredient for preventing or treating rheumatoid arthritis
WO2015176012A1 (en) 2014-05-15 2015-11-19 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN113440506A (zh) 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
NZ749389A (en) 2016-06-08 2022-12-23 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN107382710B (zh) * 2017-08-19 2020-11-06 中国铁道科学研究院集团有限公司铁道建筑研究所 一种接枝抗氧剂分子的多元醇
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
EA202090890A1 (ru) * 2017-10-05 2020-09-03 Ресептор Холдингз, Инк. Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия
AR113750A1 (es) * 2017-10-05 2020-06-10 Receptor Holdings Inc Composiciones de hierbas con mejor biodisponibilidad
KR102054401B1 (ko) * 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
EP4053867A4 (en) * 2019-10-31 2024-01-17 Zeon Corporation FUNCTIONAL LAYER FOR ELECTROCHEMICAL ELEMENTS AND METHOD FOR MANUFACTURING SAME, FUNCTIONAL LAYER SEPARATOR FOR ELECTROCHEMICAL ELEMENTS AND METHOD FOR MANUFACTURING SAME, AND ELECTROCHEMICAL ELEMENT AND METHOD FOR MANUFACTURING SAME
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
EP4419096A4 (en) * 2021-10-18 2026-04-15 Enzychem Lifesciences Corp COMPOSITIONS AND METHODS OF TREATMENT OF MUCOUSITIS
US20250270471A1 (en) * 2022-04-21 2025-08-28 Merck Sharp & Dohme Llc Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts
WO2026013252A1 (en) * 2024-07-12 2026-01-15 Paoli Alessio A mixture of mono-, di- and triglycerides of nonanoic acid for use in the treatment of muscle atrophy, sarcopenia and muscle-injury

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4703062A (en) * 1984-01-16 1987-10-27 Baxter Travenol Laboratories, Inc. Parenteral nutrition with medium and long chain triglycerides
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US7307166B1 (en) * 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JPH02134326A (ja) * 1988-11-14 1990-05-23 Snow Brand Milk Prod Co Ltd 高度侵襲用経腸栄養剤
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
JP3132085B2 (ja) * 1991-09-06 2001-02-05 ウェルファイド株式会社 脂肪乳剤
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
WO1997019683A1 (en) * 1995-11-28 1997-06-05 B. Braun Melsungen Ag Hydrolysis-optimized lipid emulsions and use thereof
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) * 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) * 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
US6017531A (en) * 1997-06-02 2000-01-25 W. R. Grace & Co. Hydrophilic composition containing protease produced by Vibrio
EP1009383A1 (en) 1997-09-04 2000-06-21 Biozone Laboratories, Inc. Oral liposomal delivery system
CA2311124A1 (en) * 1997-11-19 1999-05-27 Hercules Incorporated Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
DE69833333T2 (de) * 1997-11-20 2006-10-19 Jhon, Gil Ja Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
CA2385989A1 (en) * 1999-09-27 2001-04-05 Andrew Nienstedt Compositions of tocol-soluble therapeutics
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DE60123603T2 (de) 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
JP5259905B2 (ja) * 2000-06-20 2013-08-07 エヌ・ブイ・ニュートリション・サイエンシス 抗菌剤として適用可能な中鎖脂肪酸
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
DK1900364T3 (da) 2001-04-18 2014-01-13 Prometic Biosciences Inc Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
BRPI0407276A (pt) * 2003-02-07 2006-01-31 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
PL1648851T3 (pl) 2003-07-25 2007-09-28 Prometic Biosciences Inc Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami
AP2007003939A0 (en) * 2004-09-03 2007-04-30 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
CZ305273B6 (cs) 2015-07-15
US8487001B2 (en) 2013-07-16
JP2010053135A (ja) 2010-03-11
EA007322B1 (ru) 2006-08-25
ZA200307778B (en) 2004-04-21
SK12772003A3 (sk) 2004-07-07
WO2002083120A3 (en) 2003-05-22
EA200301131A1 (ru) 2004-04-29
PL222876B1 (pl) 2016-09-30
CA2444463C (en) 2012-03-20
EP1900364B1 (en) 2013-09-25
DK1900364T3 (da) 2014-01-13
IL158322A (en) 2011-09-27
CY1107081T1 (el) 2012-10-24
EE200300510A (et) 2004-02-16
BG108280A (bg) 2004-09-30
NO335105B1 (no) 2014-09-15
PL223348B1 (pl) 2016-10-31
EP1900364A3 (en) 2009-09-23
IL158322A0 (en) 2004-05-12
AU2002308456B2 (en) 2005-12-22
AP1740A (en) 2007-05-10
EP1385498A2 (en) 2004-02-04
MXPA03009436A (es) 2004-12-06
TNSN03089A1 (en) 2005-12-23
CA2763637C (en) 2016-08-23
JP5026655B2 (ja) 2012-09-12
ES2295397T3 (es) 2008-04-16
CA2444463A1 (en) 2002-10-24
JP2014231519A (ja) 2014-12-11
JP5657879B2 (ja) 2015-01-21
NO20034644D0 (no) 2003-10-17
NZ528690A (en) 2005-08-26
ES2439738T3 (es) 2014-01-24
AU2006201163A1 (en) 2006-04-13
US7745488B2 (en) 2010-06-29
EP1900364A2 (en) 2008-03-19
PL366435A1 (pl) 2005-01-24
NZ541140A (en) 2006-11-30
BG66418B1 (bg) 2014-03-31
JP2004525957A (ja) 2004-08-26
DE60223670T2 (de) 2008-03-06
WO2002083120A2 (en) 2002-10-24
PT1900364E (pt) 2013-12-19
PT1385498E (pt) 2007-12-14
CZ20032685A3 (cs) 2004-06-16
HUP0303817A2 (hu) 2004-03-01
AP2003002888A0 (en) 2003-12-31
AU2006201163B2 (en) 2006-10-05
BR0208984A (pt) 2004-06-29
JP6420089B2 (ja) 2018-11-07
IL195200A0 (en) 2009-08-03
IL195200A (en) 2011-11-30
SI1385498T1 (sl) 2008-04-30
CA2763637A1 (en) 2002-10-24
EP1385498B1 (en) 2007-11-21
CN1633286A (zh) 2005-06-29
US20100279959A1 (en) 2010-11-04
US20040147599A1 (en) 2004-07-29
NO20034644L (no) 2003-11-25
DE60223670D1 (de) 2008-01-03
HUP0303817A3 (en) 2009-10-28
DK1385498T3 (da) 2008-03-25
KR20030096323A (ko) 2003-12-24
OA12506A (en) 2006-05-29

Similar Documents

Publication Publication Date Title
BR0208984A (pt) ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos
ES2179319T3 (es) Acido linoleico conjugado para mantener o aumentar el contenido de minerales de los huesos.
ATE345130T1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
PL347469A1 (en) Use of certain drugs for treating nerve root injury
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
NZ541593A (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
FI953369A7 (fi) Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi
MX2025012013A (es) Protac de irak4
ATE401088T1 (de) Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
Langell et al. Pharmacological agents for the prevention and treatment of toxic radiation exposure in spaceflight
AR016233A1 (es) Tienopirimidinas, un procedimiento para su preparacion, el empleo de las mismas para preparar un medicamento, las composiciones farmaceuticas que lascontienen, y un procedimiento para obtener estas composiciones farmaceuticas.
SG10201609131YA (en) Zinc-pga compositions and methods for treating cancer
RU2008151713A (ru) Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении
US9364512B1 (en) Aloe vera based vaping compositions
MX2010006867A (es) Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico.
ATE435643T1 (de) Verbesserte lipidzusammensetzungen und darin enthaltene derivate des 3- methoxybenzylthioharnstoffs
BR0206954A (pt) Processo de terapia para câncer
MX9304925A (es) Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer.
WO2024081428A3 (en) Selective modulators of ahr-regulated transcription and method for using such modulators to treat cancer
EA200700543A1 (ru) Замещенные пуринилпроизводные с иммуномодулирующей и химиозащитной активностью и их применение как таковых или с жирными кислотами со средней длиной цепи или глицеридами
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung